MICHAEL NARACHI
CIK 1380022 · CEO & President · last filed 2026-05-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$984.7K
Companies
4
Total Filings
46
Lifetime Open-Market Net
-$2.71M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RARE | Director | 40,441 | $24.35 | $984.7K | $0 | 13 | 2026-05-18 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | CEO & President | 8,356 | — | — | -$3.24M | 22 | 2017-10-17 |
| Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | Director | 62,500 | — | — | $500.0K | 2 | 2015-06-05 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Director | 23,900 | — | — | $27.1K | 9 | 2013-05-24 |
Recent Filings · Page 3 of 5
46 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-02-24 | RARE | Grant (A) | — | $0 | EDGAR |
| 2015-02-05 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-09-15 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +50,000 | $239.1K | EDGAR |
| 2014-02-11 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | +3,980 | $21.3K | EDGAR |
| 2014-02-06 | Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | Buy (P) | +62,500 | $500.0K | EDGAR |
| 2013-05-24 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Grant (A) | +3,800 | $0 | EDGAR |
| 2013-02-19 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-07-19 | Orexigen Therapeutics, Inc. (OREX) Delisted | Mixed | — | -$899.0K | EDGAR |
| 2012-07-13 | Orexigen Therapeutics, Inc. (OREX) Delisted | Mixed | — | -$755.9K | EDGAR |
| 2012-06-29 | Orexigen Therapeutics, Inc. (OREX) Delisted | Mixed | — | -$952.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.